ORIC
VENTE TOTALE: 7 000 titres (~84 140,00 $ US)
- Insiders
- Heyman Richard A.
- Total bought
- —
- Total sold
- $84,140
- Last activity
- 2026-07-24
- Last synced
-
2026-07-29 21:03:34
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-31
ORIC is a pre-revenue biotech with strong liquidity (score: 85) but severely weak fundamentals (score: 25), offering no revenue base or path to near-term profitability.
The first sentence of the analysis written for ORIC on 2026-08-31 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.129 | 10.555 | 10.392 | 13.677 | 15.875 | |
| Quick Ratio | 14.129 | 10.555 | 10.392 | 13.677 | 15.875 | |
| Solvency Ratio | -4.814 | -4.086 | -3.257 | -3.148 | -3.032 | |
| Cash Ratio | 2.237 | 2.391 | 1.143 | 4.344 | 14.917 | |
| Price To Earnings Ratio | -5.565 | -4.410 | -4.694 | -2.618 | -7.101 | |
| Price To Earnings Growth Ratio | 0.283 | 0.665 | 0.364 | -0.301 | 0.185 | |
| Forward Price To Earnings Growth Ratio | 0.283 | 0.665 | 0.364 | -0.301 | 0.185 | |
| Price To Book Ratio | 1.868 | 2.314 | 2.112 | 1.050 | 2.044 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -6.295 | -4.942 | -5.470 | -3.025 | -9.225 | |
| Price To Operating Cash Flow Ratio | -6.335 | -4.995 | -5.524 | -3.108 | -9.370 | |
| Debt To Assets Ratio | 0.028 | 0.012 | 0.040 | 0.048 | 0.006 | |
| Debt To Equity Ratio | 0.030 | 0.013 | 0.046 | 0.054 | 0.007 | |
| Debt To Capital Ratio | 0.029 | 0.013 | 0.044 | 0.052 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.011 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.069 | 1.128 | 1.137 | 1.126 | 1.094 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.553 | -4.534 | -4.188 | -4.883 | -3.930 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | 1.011 | 1.010 | 1.028 | 1.016 | |
| Debt Service Coverage Ratio | -38.513 | 0.000 | -36.215 | -16.177 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -34.695 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -34.044 | 0.000 | -31.137 | -28.260 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -9.814 | -35.395 | -8.390 | -6.211 | -30.914 | |
| Capital Expenditure Coverage Ratio | -159.223 | -94.833 | -100.928 | -36.161 | -63.409 | |
| Dividend Paid And Capex Coverage Ratio | -159.223 | -94.833 | -100.928 | -36.161 | -63.409 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.334 | -3.996 | -4.617 | -2.084 | -4.290 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.129 | ▲3.574 | ▲1.203 |
| Quick Ratio | 14.129 | ▲3.574 | ▲1.203 |
| Solvency Ratio | -4.814 | ▼-0.728 | ▼-1.147 |
| Cash Ratio | 2.237 | ▼-0.154 | ▼-2.769 |
| Price To Earnings Ratio | -5.565 | ▼-1.155 | ▼-0.687 |
| Price To Earnings Growth Ratio | 0.283 | ▼-0.382 | ▲0.044 |
| Forward Price To Earnings Growth Ratio | 0.283 | ▼-0.382 | ▲0.044 |
| Price To Book Ratio | 1.868 | ▼-0.446 | ▼-0.009 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -6.295 | ▼-1.353 | ▼-0.504 |
| Price To Operating Cash Flow Ratio | -6.335 | ▼-1.340 | ▼-0.468 |
| Debt To Assets Ratio | 0.028 | ▲0.017 | ▲0.001 |
| Debt To Equity Ratio | 0.030 | ▲0.017 | 0.000 |
| Debt To Capital Ratio | 0.029 | ▲0.016 | ▲0.000 |
| Long Term Debt To Capital Ratio | 0.011 | ▲0.011 | ▲0.009 |
| Financial Leverage Ratio | 1.069 | ▼-0.058 | ▼-0.041 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.553 | ▼-1.018 | ▼-0.935 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▼-0.004 | ▼-0.008 |
| Debt Service Coverage Ratio | -38.513 | ▼-38.513 | ▼-20.332 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲6.939 |
| Short Term Operating Cash Flow Coverage Ratio | -34.044 | ▼-34.044 | ▼-15.356 |
| Operating Cash Flow Coverage Ratio | -9.814 | ▲25.581 | ▲8.331 |
| Capital Expenditure Coverage Ratio | -159.223 | ▼-64.390 | ▼-68.312 |
| Dividend Paid And Capex Coverage Ratio | -159.223 | ▼-64.390 | ▼-68.312 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.334 | ▼-1.337 | ▼-1.269 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $718.2M | $562.7M | $473.3M | $233.6M | $557.9M | |
| Enterprise value | $684.0M | $506.5M | $460.2M | $178.8M | $333.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.03x | -4.50x | -5.37x | -2.38x | -5.61x | |
| EV / Free cash flow | -6.00x | -4.45x | -5.32x | -2.32x | -5.52x | |
| EV / EBITDA | -5.33x | -4.00x | -4.62x | -2.08x | -4.29x | |
| Net debt / EBITDA | 0.27x | 0.44x | 0.13x | 0.64x | 2.88x | |
| Current ratio | 14.13x | 10.55x | 10.39x | 13.68x | 15.88x | |
| Income quality | 0.88x | 0.88x | 0.85x | 0.84x | 0.76x | |
| Graham net-net | $3 | $3 | $3 | $4 | $6 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 102.7% | 100.0% | |
| Working capital | $268.0M | $237.4M | $192.1M | $195.1M | $225.4M | |
| Invested capital | $277.1M | $240.3M | $204.1M | $209.3M | $227.8M | |
| Return on assets | -31.5% | -46.6% | -39.5% | -35.6% | -26.4% | |
| Operating ROA | -41.7% | -54.0% | -43.9% | -33.4% | -26.4% | |
| Return on tangible assets | -31.5% | -46.6% | -39.5% | -35.6% | -26.4% | |
| Return on equity | -33.7% | -52.6% | -44.9% | -40.1% | -28.8% | |
| Return on invested capital | -36.3% | -56.6% | -46.7% | -38.6% | -27.6% | |
| Return on capital employed | -36.6% | -57.3% | -47.3% | -39.1% | -27.8% | |
| Earnings yield | -18.0% | -22.7% | -21.3% | -38.2% | -14.1% | |
| Free cash flow yield | -15.9% | -20.2% | -18.3% | -33.1% | -10.8% | |
| Capex / Op. cash flow | -0.6% | -1.1% | -1.0% | -2.8% | -1.6% | |
| Capex / Depreciation | 58.4% | 107.3% | 82.3% | 215.1% | 104.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1144d | 510d | 334d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1144d | -510d | -334d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+27.6%EV / Sales n/aEV / EBITDA ▼-33.5%EV / Op. cash flow ▼-1.538Earnings yield ▲+0.047
Profitability
Return on equity ▲+0.189Return on assets ▲+0.151Return on invested capital ▲+0.203Return on capital employed ▲+0.207Operating ROA ▲+0.123Income quality ▼-0.006Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+633.659Operating cycle n/aCash conversion cycle ▼-633.659Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+3.574Net debt / EBITDA ▼-0.178Working capital ▲+30645000.000Invested capital ▲+36794000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+28.7%EV / Sales n/aEV / EBITDA ▼-24.3%EV / Op. cash flow ▼-0.427Earnings yield ▼-0.039
Profitability
Return on equity ▼-0.048Return on assets ▼-0.051Return on invested capital ▼-0.087Return on capital employed ▼-0.088Operating ROA ▼-0.154Income quality ▲+0.119Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.746Net debt / EBITDA ▼-2.614Working capital ▲+42678000.000Invested capital ▲+49338000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-21 ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns.
- 2026-07-20 ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
- 2026-07-14 ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”).
- 2026-07-02 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted a total of 44,400 non-qualified stock options and 7,200 restricted stock units to three new non-executive employees who began their employment with ORIC in June 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date.
- 2026-06-09 ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 2026-06-05 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
- 2026-05-27 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
- 2026-05-21 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-05-19 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-05-14 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.